Recently, semaglutide and tirzepatide—globally popular medications for weight management and type 2 diabetes—have seen a collective price reduction in the Chinese market, drawing widespread attention. This trend is primarily driven by China’s national health insurance negotiations, centralized drug procurement policies, and intensifying market competition. As GLP-1 receptor agonists, semaglutide (e.g., Novo Nordisk’s Wegovy and Ozempic) and tirzepatide (Eli Lilly’s Mounjaro and Zepbound) have surged in demand due to their proven efficacy in weight loss and glycemic control. However, their high costs previously limited patient access. With domestic biosimilars and novel GLP-1 drugs accelerating development and entering the market, multinational pharmaceutical companies are proactively lowering prices to maintain market share. Inclusion in China’s national reimbursement drug list in the future could further reduce out-of-pocket expenses for patients. Experts note that price reductions not only improve accessibility but also support more cost-effective chronic disease management. Nevertheless, appropriate prescribing practices remain essential to prevent misuse or off-label use that could pose health risks.
近期，全球热门减肥与糖尿病治疗药物司美格鲁肽（Semaglutide）和替尔泊肽（Tirzepatide）在中国市场出现集体降价现象，引发广泛关注。这一趋势主要源于国家医保谈判、集采政策推进以及市场竞争加剧。作为GLP-1受体激动剂类药物，司美格鲁肽（如诺和诺德的Wegovy、Ozempic）和替尔泊肽（礼来的Mounjaro、Zepbound）凭借显著的减重和控糖效果，近年来需求激增。然而高昂价格一度限制其可及性。随着国产同类药物加速研发上市，跨国药企为抢占市场份额主动下调价格。此外，若未来纳入国家医保目录，将进一步降低患者负担。专家指出，降价不仅有助于提升药物可及性，也有望推动慢病管理向更高效、经济的方向发展。但同时也需关注用药规范，避免滥用或非适应症使用带来的健康风险。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6201.html